We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Caspase-2 Drives Progression of Fatty Liver Disease

By LabMedica International staff writers
Posted on 25 Sep 2018
Print article
Image: A photomicrograph of a fibrotic liver section revealed by staining of collagen accumulation in a mouse with human-like NASH (Photo courtesy of the University of California, San Diego).
Image: A photomicrograph of a fibrotic liver section revealed by staining of collagen accumulation in a mouse with human-like NASH (Photo courtesy of the University of California, San Diego).
The enzyme caspase-2 has been shown to be critically linked to the progression of nonalcoholic fatty liver disease (NAFLD) to the more serious and aggressive nonalcoholic steatohepatitis (NASH) form of the syndrome.

NASH is the most aggressive form of non-alcoholic fatty liver disease, which includes a spectrum of chronic liver diseases and has become a leading cause of liver transplants. NAFLD progresses to NASH in response to elevated endoplasmic reticulum (ER) stress. While the onset of simple steatosis requires elevated de novo synthesis of lipids, progression to NASH is triggered by accumulation of hepatocyte-free cholesterol.

Investigators at the University of California San Diego (USA) reported in the September 13, 2018, online edition of the journal Cell that caspase-2, whose expression was found to be ER-stress inducible and elevated in human and mouse NASH, controlled the buildup of hepatic-free cholesterol and triglycerides by activating sterol regulatory element-binding proteins (SREBP).

Caspase-2 co-localized with site 1 protease (S1P) and cleaved it to generate a soluble active fragment that initiated SCAP (SREBP cleavage-activating protein)-independent SREBP1/2 activation in the ER. Elimination of caspase-2 or its pharmacological inhibition prevented diet-induced steatosis and NASH progression in ER-stress-prone mice.

"In NASH-free individuals, the activities of SREBP1 and SREBP2 are kept under control, which is essential for preventing excessive lipid accumulation in the liver," said senior author Dr. Michael Karin, professor of pharmacology at the University of California, San Diego. "However, in NASH patients, something goes awry and the liver continues to turn out excess amounts of triglycerides and cholesterol. This correlates with elevated SREBP1 and SREBP2 activities and increased caspase-2 expression. Our results show that caspase-2 is a critical mediator of NASH pathogenesis, not only in mice but probably in humans as well. While explaining how NASH is initiated, our findings also offer a simple and effective way to treat or prevent this devastating disease."

Related Links:
University of California San Diego

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Epstein-Barr Virus Test
Mononucleosis Rapid Test
New
Unstirred Waterbath
HumAqua 5

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.